Showing results (1-10 of 20) with videos related to
Sort By:
Pageof 2
Expert Opinion on Pharmacotherapy|March 1, 2006
Duloxetine: a new selective and dual-acting antidepressantMichael Bauer, Hans-Jürgen Möller, Edith SchneiderPain Medicine (Malden, Mass.)|February 14, 2014
Patient expectations in the treatment of painful diabetic polyneuropathy: results from a non-interventional studyEdith Schneider, Dan Ziegler, Stefan Wilhelm, et al.Depression Research and Treatment|August 25, 2012
Depression treatment with duloxetine and reduction of inability to workMichael Happich, Edith Schneider, Stefan Wilhelm, et al.Journal of Diabetes and Its Complications|May 28, 2014
Impact of comorbidities on pharmacotherapy of painful diabetic neuropathy in clinical practiceDan Ziegler, Edith Schneider, Frank G Boess, et al.Journal of Clinical Pharmacology|September 5, 2002
Novel formulations of cetrorelix acetate in healthy men: pharmacodynamic effects and noncompartmental pharmacokineticsKatharina Erb, Klaus Junge, Birgit Pechstein, et al.Progress in Neuro-Psychopharmacology & Biological Psychiatry|February 10, 2007
Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophreniaPeter M Wehmeier, Michael Kluge, Edith Schneider, et al.Expert Opinion on Drug Safety|June 21, 2012
Tolerability aspects in duloxetine-treated patients with depression: Should one use a lower starting dose in clinical practice?Stefan Wilhelm, Frank G Boess, Ulrich Hegerl, et al.The Clinical Journal of Pain|December 4, 2013
Effectiveness of duloxetine compared with pregabalin and gabapentin in diabetic peripheral neuropathic pain: results from a German observational studyMichael Happich, Edith Schneider, Frank G Boess, et al.Journal of Affective Disorders|January 8, 2013
Patient preferences for outcomes of depression treatment in Germany: a choice-based conjoint analysis studyThomas M Zimmermann, Johannes Clouth, Michael Elosge, et al.BMC Psychiatry|September 22, 2011
Early reduction in painful physical symptoms is associated with improvements in long-term depression outcomes in patients treated with duloxetineEdith Schneider, Michael Linden, Harald Weigmann, et al.Pageof 2